欧康维视生物-B二零二三年年报
(Incorporated in the Cayman Islands with limited liability)(於開曼群島註冊成立的有限公司)Stock code股份代號: 1477 Virtus et Lumen勇氣和光明Virtus et Lumen勇氣和光明Virtus et Lumen勇氣和光明 2023ANNUAL REPORT年度報告 目錄 2468202846737879808183149 ʮ̡༟ࣘ 授權代表 董事會 執行董事Ye LIU Ye LIUHKFCGFCG20239302023930 註冊辦事處 非執行董事 Lian Yong CHENWei LI Vistra (Cayman) LimitedP.O. Box 31119 Grand PavilionHibiscus Way802 West Bay RoadGrand Cayman KY1-1205Cayman Islands 公司總部及中國主要營業地點 1858 審核委員會 香港主要營業地點 薪酬委員會 894417 提名委員會 開曼群島主要股份過戶登記處 Lian Yong CHEN Tricor Services (Cayman Islands) LimitedSecond Floor, Century YardCricket Square, P.O. Box 902Grand Cayman, KY1-1103Cayman Islands 聯席公司秘書 2023930HKFCGFCG20239302023930HKACGACG2023930 香港證券登記處 1831717121716 香港法律顧問 1526 核數師 •8835 股份代號 1477 公司網站www.ocumension.com ᗘߧࢩ˴ 2023 ZERVIATE®(OT-1001)NDAZERVIATE®(OT-1001)ILUVIEN®(OT-703)2023OT-1010.01%OT-702DEXYCU®(OT-502)OT-2022023OT-2022024 20232.46202255.0%2023®®2024® 2023 2023202239820231231444 2024 Lian Yong CHEN ࠅৌਕ฿ (1)(a)(i)(ii)(iii)(b)EyePointAlimera ၍ଣᄴীሞʿʱؓ 25III20231231 業務回顧 研發表現 PIOT-1001ZERVIATE®0.24%NDACDEOT-1010.01%IIIOT-5021OT-202II267005IIIIII 我們主要候選藥物的研發進展 •OT-101（0.01%硫酸阿托品滴眼液） 20236OT-101678III III •OT-1001（ZERVIATE®，0.24%西替利嗪滴眼液） 20234OT-1001NDA OT-1001 •OT-702（阿柏西普生物類似藥） 20233OT-702III OT-702IIINDA ၍ଣᄴীሞʿʱؓ •OT-502（DEXYCU®，地塞米松植入劑） 20238OT-502263 202311OT-502300III OT-502NDA •OT-202（酪氨酸激酶抑制劑） 20232IOT-202II20232IOT-202 202311OT-202213II20243OT-202IIOT-202II III •OT-703（ILUVIEN®，氟輕鬆醋酸酯玻璃體植入劑） 20231220OT-703 III 商業化表現 ®®246.455.0%10,1201,558230 202312®202411®®® 生產表現 未來發展與展望 12®2024 (i)® (ii) (iii)OT-1001NDAOT-101OT-202 (iv) 2024 ၍ଣᄴীሞʿʱؓ 財務回顧 概覽 20221231159.055.0%20231231246.4 2023123127.520221231580.0(i)(ii)EyePointAlimera 202312311,053.8 收益 20221231159.055.0%20231231246.4 (i)20221231108.888.1%20231231204.7(ii)2022123122.72023123138.32022123127.5202312313.1® 銷售成本 2022123156.082.0%20231231102.0(i)(ii)®® ၍ଣᄴীሞʿʱؓ 毛利 20221231103.040.3%20231231144.4®® 其他收入 2022123135.72023123123.2 其他收益及虧損 2022123119.9202312315.421.33.2® 銷售及營銷開支 (i)(ii)(iii)20231231226.320221231183.023.6%(i)(ii) 研發開支 123.820221231184.332.8%(i)(ii) 行政開支 (i)(ii)(iii)(iv) 20231231196.120221231190.7 所得稅開支 202312310.320220.4 年內虧損 20231231379.820221231402.65.7%41.460.527.043.2 ၍ଣᄴীሞʿʱؓ 非國際財務報告準則計量指標 貿易應收款項 3090 20231231 貿易應付款項 營運資金及資金來源 (i)(ii)(iii)(i)®®®®(ii)®®20231231842.8202212311,170.0 借款 20231231120.02022123120231270.050.03.0%3.1%20231231120.0 資本承擔 202312316.42022123149.0 或然負債 2023123120221231 資產質押 202312314.32022123126.0 ၍ଣᄴীሞʿʱؓ 資產負債比率 100%20231231 重大投資、收購及出售 20211EyePoint3,010,722EyePoint202353020231261,000,001EyePoint19,499,000152,482,000EyePoint202411120241171,910,500EyePoint37,159,000290,583,0002024111EyePoint2024117100,221EyePointEyePoint0.21% 20231231EyePoint329.12022123173.42023123110.1%20231231 20231231 重大投資或資本資產的未來計劃 外匯 僱員及薪酬 202312314442022123139820231231314.62022382.120231231 ESOPRSU20212021 ԫʿ৷ॴ၍ଣᄴ฿ᚎ 董事 執行董事 •YeLIU5220188120181123Liu Liu23201410201872009220149LiuLiu20211EyePoint Liu2003819937 •512018932020424202061 232006720188 200231999319967 非執行董事 •LianYong CHEN612018523201852320204282021720 Chen276Dimensions Capital2012 2019823Chen248720195Chen111YI201512022316255220181029202179261620141220215246037182008520143ChenFIL Capital Management (Hong Kong) Limited Chen199161991819921219847 •WeiLI522018413201841320204282021720 Li23CreacionVentures L.P.2017106Dimensions Capital20157WuXiHealthcare Ventures2015122022531 Li1998112003619937 ԫʿ৷ॴ၍ଣᄴ฿ᚎ •402019618 14GeneralAtlantic LLC2007122011120113Boyu Capital Group Management Ltd.20164201732019520231201610202136078201942021360308720192202112699620205202112212620165226920182Viela Bio, Inc.VIE20213 20065 •332021319 General Atlantic Service Company, L.P.GeneralAtlantic Service Company,L.P. 20136 獨立非執行董事 •692020623 20002017201020122011201420072012 1406250000060966151526161105104C87001 19757 ԫʿ৷ॴ၍ଣᄴ฿ᚎ •692020623 201652019122009620151 19897198212 •4822Thea2 Milk CompanyLimitedATMA2M20121020192TMOAPAC20113201210APAC2008420113TOM201953666 19982010BiMBA 高級管理層 •YeLIU52201881 •51202061 40202111 20189202112015420188201010201532009620109 2009520066 •382023112 202011202312018120201120162201812013920161Sullivan & Cromwell LLP 202111200912 ԫʿ৷ॴ၍ଣᄴ฿ᚎ •4620231GMP20198202312017320198GMPGMP20007201736016072607QA 20007 •412024120235202312202210202352019420221020159201932013820159 20056201062010720127 •532019102820236 3320163201910AlconHong Kong Ltd.201532016420132201412STAARSurgical CompanySTAAAPACAPAC20101120131 20032005200361997719917 聯席公司秘書 •382023930 •292023930202171 20209202166562017420209600332874 2016112023320237 董事資料變動 13.51B(1) Άุ၍طజѓ 企業管治常規 20231231 公司文化 20207SloganVirtuset Lumen1 819 董事會 (1)職責 (2)董事及高級管理層的責任保險及彌償保證 (3)董事會組成 執行董事 Ye LIU 非執行董事 Lian Yong CHENWei LI 獨立非執行董事 3.10(1)3.10(2)3.10A3.10(2) Άุ၍طజѓ (4)董事會成員多元化政策 13.92 3369 2024 (5)可計量目
